Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Stability Testing of Analyte in Plasma – V 2.0

Posted on By

BA-BE Studies: SOP for Stability Testing of Analyte in Plasma – V 2.0

Standard Operating Procedure for Stability Testing of Analyte in Plasma for BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/173/2025
Supersedes SOP/BA-BE/173/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To outline the procedure for evaluating the stability of analytes in plasma samples under various conditions to ensure the integrity of study samples analyzed during bioavailability/bioequivalence (BA/BE) studies.

2. Scope

This SOP applies to all stability tests conducted on plasma samples for validating storage and handling conditions during method validation and sample analysis phases of BA/BE studies.

3. Responsibilities

  • Analyst: Performs stability experiments as per protocol and records results.
  • Reviewer/Supervisor: Verifies stability data and compliance with acceptance criteria.
  • QA: Reviews documentation and ensures regulatory adherence.
See also  BA-BE Studies: SOP for Post-Dosing Restrictions and Observations - V 2.0

4. Accountability

The Bioanalytical Lab Manager is accountable for ensuring that plasma sample stability data is valid, reproducible, and documented in accordance with ICH M10 and regulatory expectations.

5. Procedure

5.1 Types of Stability Tests

  1. Short-Term Stability: Room temperature exposure for 4-24 hours.
  2. Long-Term Stability: Storage at -20°C or -70°C for the validated duration (e.g., 30, 60, 90 days).
  3. Freeze-Thaw Stability: Subject samples to three freeze-thaw cycles.
  4. Post-Preparative Stability: Assess stability of processed samples kept in autosampler for 24-72 hours.

5.2 Sample Preparation

  1. Use at least six replicates for each QC level (LQC and HQC).
  2. Aliquot QCs from the same batch of plasma to reduce variability.
  3. Store stability aliquots separately from study samples.

5.3 Execution of Stability Studies

  1. Label each stability tube with:
    • Study code
    • Analyte name
    • QC level
    • Stability type
    • Date and time of experiment
  2. Expose the samples to the defined conditions (e.g., 25°C for 6 hours for short-term).
  3. Analyze stability samples alongside freshly prepared calibration standards and QCs.
See also  BA-BE Studies: SOP for Ensuring Study Staff Role Clarity - V 2.0

5.4 Data Analysis and Acceptance Criteria

  1. Calculate measured concentrations of stability samples using fresh calibration curve.
  2. Acceptance Criteria:
    • Mean concentration should be within ±15% of nominal for both LQC and HQC.
    • %CV should be ≤15% across replicates.
  3. Document findings in Annexure-1: Stability Summary Report.

5.5 Documentation and Reporting

  1. Include raw data printouts, calibration curves, and chromatograms in the stability file.
  2. Submit final stability report to QA for verification and archival.
  3. Stability summaries shall be part of the method validation or bioanalytical report.

6. Abbreviations

  • BA/BE: Bioavailability/Bioequivalence
  • LQC: Low Quality Control
  • HQC: High Quality Control
  • %CV: Percent Coefficient of Variation
  • QC: Quality Control
See also  BA-BE Studies: SOP for Compliance with ICH E6(R2) GCP Addendum - V 2.0

7. Documents

  1. Stability Summary Report – Annexure-1
  2. Raw Data Printouts
  3. Chromatographic Data Files

8. References

  • ICH M10: Bioanalytical Method Validation
  • US FDA Guidance for Industry: Bioanalytical Method Validation (2022)
  • Sponsor Method Validation Protocol

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Stability Summary Report

Type QC Level Nominal (ng/mL) Mean Measured %CV % Difference Status
Short-Term LQC 20.0 19.2 4.8 -4% Accepted
Freeze-Thaw HQC 1500.0 1523.4 3.2 +1.6% Accepted

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial issue New SOP QA Head
17/04/2025 2.0 Revised layout and included stability types ICH M10 alignment QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Sterile Injectable Manufacturing: SOP for Intramuscular Injection Batch Manufacturing – V 2.0
Next Post: Biosimilars: SOP for Pressure Vessel Safety Checks in Bioreactor Operations – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version